Oral Answers to Questions Debate
Full Debate: Read Full DebateAndrew Murrison
Main Page: Andrew Murrison (Conservative - South West Wiltshire)Department Debates - View all Andrew Murrison's debates with the Department for International Trade
(5 years, 5 months ago)
Commons ChamberThe UK aid budget is already building the capacity of security and justice institutions in developing countries. That includes support for improved prison conditions, which can facilitate the return of foreign national offenders. Since 2010, we have removed more than 48,000 FNOs from the UK, with over 5,000 removed in 2018-19.
We spend almost £1 billion a year on incarcerating more than 9,000 foreign national offenders in our prisons, many from developing countries to which we already give international assistance. Given that it is far cheaper to build a prison to requisite standards in those countries than here, does it not make sense to use our international aid budget to send these people home, using the funds from the Department for International Development?
I am advised that the Minister of State has just been elevated to the Privy Council. I congratulate him on that and wish him well, and I am sure the House will want to join me in congratulating the right hon. Gentleman.
Thank you, Mr Speaker. My hon. Friend the Member for Kettering (Mr Hollobone) knows very well that official development assistance is disbursable only in accordance with the rules set out by the OECD. There is a good argument for building prisons, in order to remove prisoners from the UK. However, ODA funds could not be used for such a purpose, since the primary intention of ODA funds is to render assistance. I would suggest very strongly that my hon. Friend speaks to our right hon. and hon. colleagues in the Home Office and the Department of Justice.
That is quite a helpful answer. Supporting the justice systems in developing countries is hugely important, but we should not make any move towards the notion of tied aid or a quid pro quo, such as was suggested in the substantive question; that would be worrying. Will the Minister make it clear that that is not a policy of the Department for International Development?
It is not a question of that not being a DFID policy; such a thing would be proscribed by the OECD and its development advisory committee. The proposal by my hon. Friend the Member for Kettering has merit, but it would not be proper for international development funds to be used for such a thing, and if we did so, it would not count towards the 0.7% to which we are committed.
When I was in the Minister’s position, I refused Foreign Office requests—indeed, instructions—to build a prison on Pitcairn to accommodate one prisoner. Will he assure me that he will not cave in?
I think I can reassure my right hon. Friend that I will in no way be caving in.
Antimicrobial resistance is a major global health threat and tackling it is a UK priority. DFID works alongside the Department of Health and Social Care and other Departments to support research on and development of new antimicrobials and diagnostic tools and to reduce the need for antimicrobials by preventing infection and enabling prompt diagnosis and treatment.
The O’Neill review makes the case that high-income countries should help low-income countries do important mitigation works in this area, with one example being reducing pollution from pharmaceutical production facilities that give rise to superbugs, which can travel round the world, including to the UK. Will my right hon. Friend outline the work we are carrying out in this area?
Yes, but before doing so, I wish to pay tribute to my hon. Friend’s work and interest in this area. He may be familiar with this, but I would like to draw his attention to the Access to Medicine Foundation, which is jointly funded by DFID, the Dutch Government and the Gates Foundation. It focuses on low-income and middle-income countries, and I particularly draw his attention to its antimicrobial resistance benchmark of 30 pharmaceutical companies, which prompts the pharmaceutical industry to do much more to bring AMR under control, including by reducing pharmaceutical pollution from the undertakings it operates.
In some countries, 80% of the total consumption of antibiotics is in the animals sector. What are we doing to support the World Health Organisation’s recommendations on stopping really important antibiotics being used for growth promotion and disease prevention in animals, rather than for their proper use, which is to treat disease?
The hon. Lady is absolutely right on that. The use of antimicrobials for food animals in this country is falling, and of course the use of antimicrobials for veterinary purposes features in the Government’s strategy “Tackling antimicrobial resistance”, which was published in January. She will also be aware that it is important to address this particular aspect of AMR, not least to address our commitments under sustainable development goal 3, which is to do with health and wellbeing.
Drug-resistant tuberculosis kills around a quarter of a million people a year, and there are half a million new cases a year and rising. Do the Government accept that full replenishment of the Global Fund will be essential if this global health threat is to be beaten?
My right hon. Friend is absolutely right to highlight TB. He will be aware of the various funds to which the UK contributes to address this global scourge, and that includes contributions to the Global Fund’s efforts to discover 150 million undiscovered cases of TB worldwide, on which it has made some inroads. My right hon. Friend will not expect me to commit here and now to the sixth replenishment, but he will be aware that we have been at the forefront of encouraging countries to do so. I expect us to be positive—as we were for the fifth replenishment—in Lyon in October.
The Global Fund directs its resources to countries with the highest disease burden and the least ability to pay and within countries to key vulnerable and marginalised populations. The UK was the second largest donor to the fund’s fifth replenishment, which is currently tackling the three big killers that the hon. Gentleman cites in his question.
Will the Minister tell me what assessment he has made of the work of the Global Fund in co-ordination with Gavi, the Vaccine Alliance, and how his Department is working to foster this collaboration so that the most vulnerable communities receive all the healthcare that they need?
Given the nature of the conditions that the Global Fund principally deals with, the hon. Gentleman is right to raise Gavi. The UK is the biggest contributor to Gavi for a very good reason—vaccination works. In dealing with those three key killers, it is clearly vital that we focus on prevention. That means not just vaccination, and Gavi does not simply vaccinate people, but dealing with a range of public health issues that are necessary in order to prevent infection happening from the beginning. This Government fully support both Gavi and the Global Fund.